According to these analysts, the Low Revenue Estimate for Gilead Sciences, Inc.is 7.22 Billion and the High Revenue Estimate is 7.98 Billion. EPS growth in past five years was 48.30% while EPS growth in next five years is projected to arrive at 0.08%. In the matter of earnings surprises, it can have a huge impact on a company’s stock price. The stock’s Dividend stands at 0.34 and Dividend Yield stands at 2.76 Percent.
Advertisement
According to the Latest Earnings results, Gilead Sciences, Inc. reported Earnings Per Share (EPS) of $3.08 whereas, the Analyst were expecting an EPS of $3.02/share. The corporation holds a 20-day simple moving average of -2.33% with a volume of -2.33%. One week ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “4” brokerage firms. The company touched its 52-Week High on Oct 29, 2015 which was $14.01 and 52-Week Low on Feb 11, 2016 as $9.88. Gilead Sciences has a 1-year low of $77.92 and a 1-year high of $113.31. The stock has market worth of $105.68B. RBC Capital Markets set a $105.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, August 11th.
Gilead Sciences (GILD): 12 investment research analysts covering Gilead Sciences (GILD) have an average price target of $108.92 for the near short term. Gilead Sciences has an average rating of “Buy” and a consensus price target of $106.82. The company’s last traded volume of 9.2 million shares was above it’s an average volume of 10.12 million shares. The shares were sold at an average price of $80.50, for a total transaction of $8,050,000.00.
Gilead Sciences, Inc. (NASDAQ:GILD) reported that its deferred compensations came to a total of $-0.13 million for the 12 month period ended 2015-12-31. While it’s Return on Investment (ROI) value is 45.9%.
The company shows its Return on Assets (ROA) value of 32.7%.
Currently, the stock carries a price to earnings ratio of 7.03, a price to book ratio of 6.85, and a price to sales ratio of 3.26. The Return on Equity (ROE) value stands at 100.8%. The stock traded in the range of $41.06 – $41.58 during its most recent trading session. Of the 12 analyst estimates, the most bullish sees the stock reaching $122 within the next 12 months while the most bearish analyst sees the stock at $93 within the year.
Advertisement
Gilead Sciences, Inc. (NASDAQ:GILD) on August 23, 2016 announced that the European Commission has granted marketing authorization for once-daily Truvada (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination with safer-sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP. Truvada was approved by the European Medicines Agency in 2005 for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults aged 18 years and over, and is now the most prescribed antiretroviral medicine in Europe as part of combination therapy. Year-to-Date the stock performance stands at -20.34%.
